Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Merck
Daiichi Sankyo
Cipla
Deloitte
US Department of Justice
Fish and Richardson
McKesson
Colorcon
Mallinckrodt

Generated: February 19, 2018

DrugPatentWatch Database Preview

QUILLICHEW ER Drug Profile

« Back to Dashboard

When do Quillichew Er patents expire, and when can generic versions of Quillichew Er launch?

Quillichew Er is a drug marketed by Pfizer Inc and is included in one NDA. There are six patents protecting this drug.

This drug has thirty-one patent family members in fourteen countries.

The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for QUILLICHEW ER
Drug patent expirations by year for QUILLICHEW ER
Pharmacology for QUILLICHEW ER

US Patents and Regulatory Information for QUILLICHEW ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-002 Dec 4, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for QUILLICHEW ER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,563,033 Orally effective methylphenidate extended release powder and aqueous suspension product ➤ Sign Up
9,180,100 Methylphenidate extended release chewable tablet ➤ Sign Up
8,062,667 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
8,597,684 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
9,522,191 Modified release formulations containing drug--ion exchange resin complexes ➤ Sign Up
9,844,545 Methylphenidate extended release chewable tablet ➤ Sign Up
8,465,765 Orally effective methylphenidate extended release powder and aqueous suspension product ➤ Sign Up
8,747,902 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
8,883,217 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for QUILLICHEW ER

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Baxter
McKinsey
Dow
Fuji
US Army
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot